Human Milk Oligosaccharides

3-Fucosyllactose (3-FL)

Please contact us for further details including product samples:

The Human Milk Oligosaccharide (HMO) 3-FL (3-Fucosyllactose) is one of the most abundant fucosylated HMOs, and particularly dominant in the milk of non-secretor mothers. 3-FL occurs in human milk in a concentration of 0.72 (± 0.7) g/L 1,2,3. While the concentration of 2-linked fucosyllactoses decrease over the lactation time, the amount of 3-FL increases in later lactation stages 4. The specific functional benefits of 3-FL include reducing the risk of infection by inhibiting the adhesion of pathogenic bacteria, e.g. Pseudomonas aeruginosa or enteropathogenic E. coli or viruses e.g. Norovirus 4,5,6. It also shows general ability to reduce colonization of non-beneficial bacteria, e.g. Enterococcus faecium, and in turn positively supporting gut health by selectively stimulating beneficial bifidobacterial 7,8. Further studies on 3-FL suggest positive effects in regulating intestinal motility.9.

Jennewein Biotechnologie produces 3-Fucosyllactose on a commercial scale under FSSC 22000 and ISO 9001 certification. The product is available as a spray-dried powder. The Jennewein 3′-Fucosyllactose product is Kosher (Orthodox Union) as well as Halal (Halal Food Council of Europe) certified.

We offer 3-Fucosyllactose (CAS 41312-47-4) with the following specification:

Product code:
1011 3-Fucosyllactose Infant formula grade ≥ 90 % (spray-dried)

 

Regulatory Applications for Jennewein 3‘-FL have already been submitted in EU (EFSA), US (FDA GRAS) and further markets.

Please contact us for further details including product samples:

 


  1. Thurl, Stephan, et al. “Variation of human milk oligosaccharides in relation to milk groups and lactational periods.” British Journal of Nutrition 104.9 (2010): 1261-1271.
  2. Thurl, Stephan, et al. “Systematic review of the concentrations of oligosaccharides in human milk.” Nutrition reviews11 (2017): 920-933.
  3. McGuire, Michelle K., et al. “What’s normal? Oligosaccharide concentrations and profiles in milk produced by healthy women vary geographically.” The American journal of clinical nutrition 105.5 (2017): 1086-1100.
  4. Borewicz, Klaudyna, et al. “The association between breastmilk oligosaccharides and faecal microbiota in healthy breastfed infants at two, six, and twelve weeks of age.” Scientific reports1 (2020): 1-12.
  5. Weichert, Stefan, et al. “Bioengineered 2′-fucosyllactose and 3-fucosyllactose inhibit the adhesion of Pseudomonas aeruginosa and enteric pathogens to human intestinal and respiratory cell lines.” Nutrition research10 (2013): 831-838.
  6. Derya, Sami M., et al. “Biotechnologically produced fucosylated oligosaccharides inhibit the binding of human noroviruses to their natural receptors.” Journal of Biotechnology (2020).
  7. Craft, Kelly M., and Steven D. Townsend. “The human milk glycome as a defense against infectious diseases: rationale, challenges, and opportunities.” ACS infectious diseases2 (2018): 77-83.
  8. Bode, Lars. “Human milk oligosaccharides: prebiotics and beyond.” Nutrition reviewssuppl_2 (2009): S183-S191.
  9. Bienenstock, John, et al. “Fucosylated but not sialylated milk oligosaccharides diminish colon motor contractions.” PLoS One10 (2013).